PLD vs. observation for advanced soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced soft tissue sarcoma (certain rare subtypes are not included).
- You finished 4 to 8 cycles of your first chemotherapy (anthracycline type).
- Your best response to that chemo was complete or partial shrinking, or stable disease.
- You start the trial within 8 weeks of your last chemo dose.
- You are 18 or older and have good physical function (ECOG 0 or 1).
- Your organs are working well (heart, liver, kidneys, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy medicines—oral cyclophosphamide versus doxorubicin—in people age 65 and older with advanced soft-tissue sarcoma that can’t be cured with surgery or radiation. It aims to see which treatment works better and is more tolerable for this age group.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Hear when a new Advanced Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.